Company profile
Haleon US Holdings
Subsidiary of Haleon plc (HLN)
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Approved | — | Migraine | |
| Approved | Nonsteroidal Anti-inflammatory DrugSmall molecule | Migraine |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.